GlassScriptPhysician profile
Samuel T Snipes
NPI 1043427438
$6,383.69
in general payments reported to CMS, 2019-2025
26 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $556 · 2021: $605 · 2022: $841 · 2023: $1,258 · 2024: $1,187 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Travel and Lodging: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.60 |
| Travel and Lodging | $863.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,306.21 | 2021-2025 | Urolift, Barrigel |
| Axonics, INC. | $742.29 | 2021-2024 | Axonics, Bulkamid |
| Coloplast Corp | $703.46 | 2019-2022 | |
| Boston Scientific Corporation | $682.08 | 2019-2025 | General - Erectile Dysfunction, Ams 800 Artificial Urinary Sphincter |
| Neotract INC. | $562.40 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $233.03 | 2019-2023 | Aveed, Xiaflex, Edex |
| Astellas Pharma US INC | $172.27 | 2019-2022 | |
| Urogen Pharma, INC. | $138.76 | 2022-2025 | |
| Endo USA, INC. | $124.93 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $121.13 | 2019-2023 | Botox |
| Blue Earth Diagnostics | $95.46 | 2019-2025 | Posluma |
| Tolmar, INC. | $73.66 | 2025 | Jatenzo, Eligard |
| Medtronic, INC. | $68.04 | 2024-2025 | Interstim |
| Myriad Genetic Laboratories, INC. | $56.18 | 2022-2025 | Prolaris |
| Urovant Sciences INC | $38.90 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $30.28 | 2025 | Gemtesa |
| Pfizer INC. | $29.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.97 | 2022 | |
| Progenics Pharmaceuticals, INC. | $26.13 | 2024 | |
| Chiesi USA, INC. | $24.49 | 2021 | |
| Cook Medical LLC | $24.41 | 2024 | Roadrunner |
| Myovant Sciences INC. | $23.90 | 2022 | |
| Antares Pharma, INC. | $22.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.14 | 2024 | Adstiladrin |
| C. R. Bard, INC. & Subsidiaries | $18.22 | 2025 | Bard Urinary Drainage Bag |
| Procept Biorobotics Corporation | $17.16 | 2024 | Aquabeam System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Snipes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.